The Binding Site

The Binding Site The Specialist Protein Company

Binding Site, Part of Thermo Fisher Scientific, is committed to improving patient lives worldwide through education, collaboration and innovation. Binding Site provide diagnostic solutions that help doctors, clinicians and laboratory researchers across the globe diagnose and monitor blood cancers and immune system disorders. Founded by researchers at the University of Birmingham, Binding Site has continued to build on its strong scientific foundations, supporting research and development within our field and responding to the changing needs of patients, researchers and clinicians for over 30 years. We are committed to working in collaboration with our partners and customers to lead the way in specialized medical diagnostics, ensuring we continue to make a difference together.

Veskovski et al. (2024) highlights several patient cases in which the choice of serum free light chain assay significant...
20/10/2025

Veskovski et al. (2024) highlights several patient cases in which the choice of serum free light chain assay significantly impacted the patients’ lives.

For over 20 years, Freelite® tests have been the trusted serum free light chain assay within the global medical and scientific community.

Learn more about how Freelite assays transformed patient journeys and improved patient’s lives: http://spr.ly/6180xb1Jg

Freelite® assays play a pivotal role in accurate diagnosis, treatment monitoring, and disease management to provide a be...
13/10/2025

Freelite® assays play a pivotal role in accurate diagnosis, treatment monitoring, and disease management to provide a better patient outcome.

Read these patient cases which reinforce why Freelite assays have been trusted by the medical community worldwide for over 20 years. http://spr.ly/6180xb1Jg

10/10/2025

Explore how Freelite® assays have impacted and transformed patients’ lives. From early detection to guiding treatment decisions, Freelite assays empower healthcare professionals to make better-informed choices for their patients.

Explore this series of patient cases highlighting why clinicians and laboratories worldwide trust the serum free light chain assay by Binding Site: http://spr.ly/6185AtpVN

We are live at AAFP FMX. Visit the Binding Site booth ( #380) to meet our team and learn more about how Freelite® assays...
08/10/2025

We are live at AAFP FMX. Visit the Binding Site booth ( #380) to meet our team and learn more about how Freelite® assays can support earlier detection of multiple myeloma in primary care. Our experts are available throughout the day to answer questions and share insights on the importance of timely testing in improving patient outcomes.

We are thrilled to announce the appointment of Stephen Harding as our new Vice President and General Manager.With over 2...
07/10/2025

We are thrilled to announce the appointment of Stephen Harding as our new Vice President and General Manager.

With over 23 years in diagnostics and life sciences, Ste has been instrumental in our journey—from developing Freelite® Assays and launching the Optilite® Analyser, to collaborating on the iStopMM screening study and introducing the EXENT® System. His innovative vision and global partnerships continue to drive impactful diagnostics.

Stephen Harding "Together, we’ll keep advancing innovation in protein diagnostics and delivering impact where it matters most. I’m excited to work alongside our exceptional team as we write the next chapter of Binding Site, part of Thermo Fisher Scientific." Read more 👉 http://spr.ly/6182AUVds

Join us at AAFP FMX for our educational session, From the patient journey to clinical insights: What primary care needs ...
06/10/2025

Join us at AAFP FMX for our educational session, From the patient journey to clinical insights: What primary care needs to know about multiple myeloma.

Date: Wednesday, October 8
Time: 8:00–8:30 a.m.
Location: Room 207CD

This session will explore the critical role of primary care in identifying nonspecific symptoms, recognizing higher-risk populations, and ordering essential diagnostic tests like Freelite® assays.



This program is not for CME credit and is consistent with the PhRMA Code on Interactions with Health Care Professionals.

Binding Site is heading to AAFP FMX 2025 in Anaheim, October 5–9. Visit the Binding Site booth ( #380) to connect with o...
02/10/2025

Binding Site is heading to AAFP FMX 2025 in Anaheim, October 5–9. Visit the Binding Site booth ( #380) to connect with our team and learn more about the role of Freelite® assays in supporting earlier detection of multiple myeloma. We look forward to meaningful discussions with family medicine and primary care professionals.

Fatigue. Bone pain. Recurrent infections. These symptoms may seem benign, but in some patients, they may indicate blood ...
29/09/2025

Fatigue. Bone pain. Recurrent infections.

These symptoms may seem benign, but in some patients, they may indicate blood cancers such as multiple myeloma.

Early detection is critical to improving outcomes. Clinical vigilance is essential when symptoms persist or are unexplained.

Learn more: http://spr.ly/6189AKPgb

Multiple Myeloma often presents with nonspecific symptoms that can easily be attributed to aging, which makes early diag...
29/09/2025

Multiple Myeloma often presents with nonspecific symptoms that can easily be attributed to aging, which makes early diagnosis challenging. This delay in diagnosis can significantly impact patient outcomes. Therefore, early detection is critical as it can improve treatment options, increase survival rates, and enhance the quality of life for patients.

The International Myeloma Working Group recommends specific tests to identify monoclonal proteins, which can help in the diagnosis of this condition.

25/09/2025

"🌲Early Christmas Sale 🎁 Start your mornings right with these awesome mineral rock coffee mugs!
☕️Shop now : https://bit.ly/thermofishere

24/09/2025

Our team is ready to welcome you at the IBMS Congress 2025! Visit our booth and discover how the EXENT and Optilite systems is transforming diagnostic testing and hear from our experts on the latest trends and advancements.

Join us on September 24, 2025, at 2:00 pm ET / 11:00 am PT for a webinar focused on addressing diagnostic delays in mult...
23/09/2025

Join us on September 24, 2025, at 2:00 pm ET / 11:00 am PT for a webinar focused on addressing diagnostic delays in multiple myeloma.

Dr. Joseph Mikhael from the International Myeloma Foundation will share practical insights for primary care providers, including challenges around
nonspecific symptoms, health disparities, and low confidence in test interpretation revealed in a national survey of US primary care providers.

Key topics include:

• Signs and symptoms of multiple myeloma and monoclonal gammopathies
• Delayed diagnosis and health disparities
• Improving test confidence and care coordination

Register here: http://spr.ly/6181AKrSc

Address

8 Calthorpe Road, Edgbaston
Birmingham
B151QT

Opening Hours

Monday 7:30am - 5pm
Tuesday 7:30am - 5pm
Wednesday 7:30am - 5pm
Thursday 7:30am - 5pm
Friday 7:30am - 5pm

Telephone

+441214569500

Website

Alerts

Be the first to know and let us send you an email when The Binding Site posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to The Binding Site:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category